Macrophage Gadd45b Emerges as Key Driver of Inflammation-Linked Liver Cancer

Liver cancer rarely arises in a healthy organ. In most cases, hepatocellular carcinoma, the most common form of primary liver cancer, develops after years of chronic injury, and one of the fastest-growing routes to this endpoint is metabolic dysfunction-associated steatohepatitis, known as MASH. A new study published in Experimental & Molecular Medicine offers a refined view of how this inflammatory liver disease progresses toward malignancy, and it points to an unexpected orchestrator of that process: a stress-response protein called Gadd45b inside macrophages, the immune cells that populate inflamed liver tissue.

The research, led by investigators working to improve experimental models of the MASH-to-cancer transition, addresses a persistent gap in liver disease research. Existing animal models of MASH-driven hepatocellular carcinoma often fail to reproduce the slow, inflammation-heavy sequence of events seen in patients, in which fatty liver disease, chronic immune activation, fibrosis and eventually tumor formation unfold over years or decades. Without faithful models, researchers have struggled to identify the molecular switches that convert a wound-healing response into a cancer-promoting environment.

To close that gap, the team refined an experimental MASH–HCC model designed to capture the inflammatory milieu more accurately, combining metabolic stress with the kind of sustained immune signaling that characterizes human disease. The goal was not simply to make tumors appear faster, but to recreate the biological context in which inflammation actively reshapes the liver’s cellular landscape and drives pre-malignant cells toward full neoplastic transformation.

Using this refined platform, the researchers systematically examined the roles of immune cell populations within the tumor microenvironment. Macrophages, long recognized as versatile players that can either restrain or support tumor growth, emerged as central figures. Their internal molecular machinery, rather than their mere presence, appeared to determine the trajectory of disease. At the heart of that machinery sat Gadd45b, a protein belonging to the growth arrest and DNA damage-inducible family, best known for its involvement in cellular stress responses, DNA repair signaling and the regulation of inflammatory pathways.

Gadd45b has previously been implicated in immune regulation in several contexts, but its function inside tumor-associated macrophages during liver cancer development had remained poorly defined. The new work positions it as a key orchestrator of inflammation-driven neoplastic progression. According to the study’s findings, macrophage Gadd45b helps shape the signaling environment that fuels the proliferation and survival of pre-cancerous liver cells, effectively linking chronic inflammatory stimulation to the cellular events that culminate in hepatocellular carcinoma.

From a technical standpoint, the study’s strength lies in its integrated approach. By coupling a physiologically relevant disease model with mechanistic interrogation of macrophage biology, the researchers could move beyond correlation. Altering Gadd45b function in macrophages changed the course of neoplastic progression in the refined model, supporting the interpretation that this protein is not a passive bystander but an active regulator of the inflammatory program that drives cancer formation. The findings suggest that the epigenetic and transcriptional state of macrophages may be a decisive factor in whether a chronically inflamed liver progresses to malignancy.

The broader significance of this work rests on the biology of MASH itself. As obesity and metabolic syndrome rates climb worldwide, MASH has become one of the fastest-growing liver diseases and a rapidly expanding risk factor for hepatocellular carcinoma. Patients with MASH-related liver cancer often present at advanced stages, and therapeutic options remain limited. Understanding the immune-mediated mechanisms that connect steatohepatitis to tumor formation is therefore considered a priority for developing preventive strategies and earlier interventions.

Macrophages are particularly attractive targets in this context. Unlike malignant cells, which accumulate mutations that make them unstable therapeutic targets, macrophages are genetically stable and highly responsive to their environment. If a single intracellular factor such as Gadd45b controls whether these cells adopt a tumor-promoting state, it opens the possibility of reprogramming the inflammatory microenvironment before cancer takes hold. Such an approach would not attack tumor cells directly but would instead dismantle the ecological niche they depend upon, an increasingly popular strategy in modern cancer research.

The study also underscores the value of model refinement in biomedical research. Many promising findings in liver cancer biology have failed to translate because standard mouse models compress or bypass key stages of human disease. By building a system that more faithfully reproduces the inflammatory architecture of MASH-associated cancer, the researchers have created a tool that can be used to test candidate mechanisms and therapies under conditions that better mirror the clinical reality. This methodological contribution may prove as consequential as the Gadd45b finding itself, offering the field a more reliable framework for studying inflammation-driven carcinogenesis.

Looking ahead, the identification of macrophage Gadd45b as a key orchestrator of the MASH–HCC transition raises a series of testable questions. Researchers will need to determine whether Gadd45b expression in macrophages correlates with disease progression in human liver samples, whether it can serve as a biomarker of elevated cancer risk in patients with MASH, and whether pharmacological modulation of the Gadd45b pathway can safely dampen tumor-promoting inflammation without impairing the liver’s essential wound-healing responses. The answers could shape a new generation of therapies aimed not at the tumor itself, but at the inflammatory soil in which it grows, marking a meaningful step toward interrupting one of the most consequential disease trajectories in modern hepatology.

Subject of Research: The role of macrophage Gadd45b in inflammation-driven progression from MASH to hepatocellular carcinoma

Article Title: A refined MASH–HCC model identifies macrophage Gadd45b as a key orchestrator of inflammation-driven neoplastic progression

Article References: Kim, H., Kim, G., Yeon, H., Yang, D.-Y., Lee, S. G., An, T. H., Oh, S. Y., Yoon, S., Kim, J., Choi, J., Park, H.-J., Lee, E.-W., Han, B.-S., Lee, C.-H., Kim, I. Y., Kim, W. K., Bae, K.-H., Park, J. W., Oh, S. H., … Oh, K.-J. (2026). A refined MASH–HCC model identifies macrophage Gadd45b as a key orchestrator of inflammation-driven neoplastic progression. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01838-5

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01838-5

Keywords: MASH, hepatocellular carcinoma, macrophages, Gadd45b, inflammation, liver cancer, tumor microenvironment, metabolic dysfunction-associated steatohepatitis, neoplastic progression, cancer immunology, disease models, Experimental & Molecular Medicine